ArticleCell communication and signaling : CCS2026
GSK'872 mitigates ischemia-reperfusion injury in rat lung transplants by regulating PANoptosis and inflammation in cell type specific manner.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundIschemia-reperfusion injury (IRI) greatly impairs lung transplantation (LTx) outcomes, with no effective treatments. Although existing studies have confirmed that cell death and inflammation responses are critical in LTx-IRI, the specific cell death profiles of various parenchymal and inflammatory cells remain to be elucidated.
methodsUsing human single-cell RNA sequencing data from LTx-IRI, we identified activation of genes related to cell death and inflammation pathways. We examined the effects and mechanisms of a RIPK3 inhibitor, GSK'872, on IRI with a rat LTx model.
resultsGSK'872, added to lung preservation solution, injected to recipients, or in combination, reduced alveolar hemorrhage, perivascular edema, neutrophil infiltration and suppressed necroptosis, pyroptosis, and inflammation in lung tissues. GSK'872 decreased MLKL phosphorylation in type 2 alveolar epithelial cells and macrophages, and RIPK3 phosphorylation in neutrophils. GSK'872 induced apoptosis in RAW264.7 macrophages via RIPK1 and caspase 3 cleavage in a cold ischemia/warm reperfusion (CI/R) cell culture model. GSK'872 inhibited lipopolysaccharide (LPS)-stimulated neutrophil extracellular traps (NETs) formation with suppressed necroptosis and pyroptosis. GSK'872 did not rescue BEAS-2B lung epithelial cells from CI/R-induced cell death. However, conditioned medium from GSK'872-treated macrophages (after CI/R) or neutrophils (challenged by LPS) reduced CI/R-induced decrease in BEAS-2B cell viability.
conclusionsGSK'872 alleviates LTx-IRI by inhibiting necroptosis and pyroptosis in macrophages and neutrophils directly, and protects lung epithelial cells via blocking soluble mediators indirectly. Administration of GSK'872 to lung preservation solution and/or injection to recipients may be new treatment options for IRI in LTx.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.